Bio-Reference Laboratories Beats Analyst Estimates on EPS

Seth Jayson, The Motley Fool
Updated

Bio-Reference Laboratories (NAS: BRLI) reported earnings on Aug. 30. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended July 31 (Q3), Bio-Reference Laboratories met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share increased significantly.


Gross margins dropped, operating margins grew, net margins improved.

Revenue details
 Bio-Reference Laboratories tallied revenue of $172.3 million. The six analysts polled by S&P Capital IQ predicted a top line of $173.1 million on the same basis. GAAP reported sales were 16% higher than the prior-year quarter's $148.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.45. The six earnings estimates compiled by S&P Capital IQ anticipated $0.42 per share. GAAP EPS of $0.45 for Q3 were 25% higher than the prior-year quarter's $0.36 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 49.9%, 160 basis points worse than the prior-year quarter. Operating margin was 13.2%, 80 basis points better than the prior-year quarter. Net margin was 7.3%, 50 basis points better than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $175.7 million. On the bottom line, the average EPS estimate is $0.46.

Next year's average estimate for revenue is $661.7 million. The average EPS estimate is $1.51.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 309 members out of 329 rating the stock outperform, and 20 members rating it underperform. Among 100 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 95 give Bio-Reference Laboratories a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bio-Reference Laboratories is outperform, with an average price target of $28.40.

The article Bio-Reference Laboratories Beats Analyst Estimates on EPS originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Bio-Reference Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement